<DOC>
	<DOCNO>NCT01636492</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled , dose-escalating study evaluate safety , tolerability , pharmacokinetics pharmacodynamics bitopertin healthy male volunteer . Subjects randomize cohort receive single oral dos either bitopertin placebo .</brief_summary>
	<brief_title>A Study Bitopertin ( RO4917838 ) Healthy Male Volunteers</brief_title>
	<detailed_description />
	<criteria>Male healthy volunteer , 18 60 year age inclusive Body mass index ( BMI ) 1935 kg/m2 inclusive Supine blood pressure within normal range center heart rate &gt; /= 40 provide QTcB &lt; 450 ms Subjects must agree use barrier method contraception ( e.g . condom ) duration study 30 day study completion History evidence clinically significant disease disorder Clinically significant ECG abnormality Positive hepatitis B , hepatitis C HIV infection Previous treatment iron iron deficiency anemia Regular smoker ( &gt; 10 cigarette , &gt; 3 pipeful &gt; 3 cigar per day ) History alcohol and/or drug abuse addiction within last 2 year study start Any confirm significant allergic reaction drug , multiple allergy judgment investigator Participation clinical study investigational drug within last three month prior screen Any condition disease detect medical interview/physical examination would render subject unsuitable study , place subject undue risk interfere ability subject complete study opinion investigator designee</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>